MedTrace Logo

Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer

NCT03299478 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 865

Last updated 2024-06-11

No results posted yet for this study

Summary

The purpose of this study is to validate TNM-Immunoscore in resected non-small cell lung cancer.

Conditions

Interventions

OTHER

Will look for immune infiltration

Sponsors & Collaborators

  • Norwegian Cancer Society

    collaborator OTHER

  • Northern Health Authority

    collaborator OTHER_GOV

  • St. Olavs Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Oslo University Hospital

    collaborator OTHER

  • University of Tromso

    collaborator OTHER

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Lill-Tove R Busund, MD, PhD · University Hospital of North Norway

  • Sigve Andersen, MD,PhD · University Hospital of North Norway

  • Tom Dønnem, MD,PhD · University Hospital of North Norway

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-28
Primary Completion
2027-02-01
Completion
2027-02-01

Countries

  • Denmark
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03299478 on ClinicalTrials.gov